Increased Immunogenicity and Protective Efficacy of Influenza M2e Fused to a Tetramerizing Protein

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Andersson, Anne Marie Carola ^a   Håkansson, Kjell O ^a   Jensen, Benjamin Anderschou Holbech ^a   Christensen, Dennis ^b   Andersen, Peter ^b   Thomsen, Allan Randrup ^a   Christensen, Jan Pravsgaard ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; M2E PEPTIDE; ROTAVIRUS NONSTRUCTURAL PROTEIN 4; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; HELA CELL; HUMAN; HUMAN CELL; IMMUNOGENICITY; INFLUENZA A; INFLUENZA VIRUS A; MOUSE; NONHUMAN; PROVOCATION TEST; VIRUS IMMUNITY; VIRUS LOAD;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; CHROMATOGRAPHY, AFFINITY; CLONING, MOLECULAR; DNA PRIMERS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GLYCOPROTEINS; HELA CELLS; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; KAPLAN-MEIER ESTIMATE; LUNG; MICE; MOLECULAR SEQUENCE DATA; ORTHOMYXOVIRIDAE INFECTIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; TOXINS, BIOLOGICAL; VIRAL LOAD; VIRAL MATRIX PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

INFLUENZA A VIRUS; MURINAE; ROTAVIRUS;

EID: 84867024604     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046395     Document Type: Article

References (35)

1. Ellebedy AH, Webby RJ, (2009) Influenza vaccines. Vaccine 27Suppl 4: D65-D68.
2. Schnell JR, Chou JJ, (2008) Structure and mechanism of the M2 proton channel of influenza A virus. Nature 451: 591-595.
3. Fiers W, De FM, Birkett A, Neirynck S, Min JW, (2004) A "universal" human influenza A vaccine. Virus Res 103: 173-176.
4. Ito T, Gorman OT, Kawaoka Y, Bean WJ, Webster RG, (1991) Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. J Virol 65: 5491-5498.
5. Zebedee SL, Lamb RA, (1989) Nucleotide sequences of influenza A virus RNA segment 7: a comparison of five isolates. Nucleic Acids Res 17: 2870.
6. Soboleski MR, Gabbard JD, Price GE, Misplon JA, Lo CY, et al. (2011) Cold-adapted influenza and recombinant adenovirus vaccines induce cross-protective immunity against pH1N1 challenge in mice. PLoS One 6: e21937.
7. De FM, Martens W, Smet A, Schotsaert M, Birkett A, et al. (2008) Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine 26: 6503-6507.
8. Fan J, Liang X, Horton MS, Perry HC, Citron MP, et al. (2004) Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22: 2993-3003.
9. Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, et al. (2008) Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26: 201-214.
10. Jegerlehner A, Schmitz N, Storni T, Bachmann MF, (2004) Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 172: 5598-5605.
11. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, et al. (1999) A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5: 1157-1163.
12. Zebedee SL, Lamb RA, (1988) Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 62: 2762-2772.
13. Feng J, Zhang M, Mozdzanowska K, Zharikova D, Hoff H, et al. (2006) Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol J 3: 102.
14. Zhao G, Lin Y, Du L, Guan J, Sun S, et al. (2010) An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol J 7: 9.
15. Mozdzanowska K, Feng J, Eid M, Kragol G, Cudic M, et al. (2003) Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 21: 2616-2626.
16. De FM, Martens W, Roose K, Deroo T, Vervalle F, et al. (2008) An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem 283: 11382-11387.
17. Okuda K, Ihata A, Watabe S, Okada E, Yamakawa T, et al. (2001) Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene. Vaccine 19: 3681-3691.
18. Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, et al. (2007) Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 13: 426-435.
19. Wu F, Yuan XY, Huang WS, Chen YH, (2009) Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine. Vaccine 27: 6095-6101.
20. Fu TM, Freed DC, Horton MS, Fan J, Citron MP, et al. (2009) Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus. Virology 385: 218-226.
21. Grandea AG III, Olsen OA, Cox TC, Renshaw M, Hammond PW, et al. (2010) Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci U S A 107: 12658-12663.
22. Bowman GD, Nodelman IM, Levy O, Lin SL, Tian P, et al. (2000) Crystal structure of the oligomerization domain of NSP4 from rotavirus reveals a core metal-binding site. J Mol Biol 304: 861-871.
23. Agger EM, Rosenkrands I, Hansen J, Brahimi K, Vandahl BS, et al. (2008) Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One 3: e3116.
24. Christensen D, Agger EM, Andreasen LV, Kirby D, Andersen P, et al. (2009) Liposome-based cationic adjuvant formulations (CAF): past, present, and future. J Liposome Res 19: 2-11.
25. Fomsgaard A, Karlsson I, Gram G, Schou C, Tang S, et al. (2011) Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01. Vaccine 29: 7067-7074.
26. Christensen D, Korsholm KS, Andersen P, Agger EM, (2011) Cationic liposomes as vaccine adjuvants. Expert Rev Vaccines 10: 513-521.
27. Spackman E, Senne DA, Myers TJ, Bulaga LL, Garber LP, et al. (2002) Development of a real-time reverse transcriptase PCR assay for type A influenza virus and the avian H5 and H7 hemagglutinin subtypes. J Clin Microbiol 40: 3256-3260.
28. Sui J, Hwang WC, Perez S, Wei G, Aird D, et al. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16: 265-273.
29. Prabhu N, Prabakaran M, Ho HT, Velumani S, Qiang J, et al. (2009) Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection. J Virol 83: 2553-2562.
30. Corti D, Suguitan AL Jr, Pinna D, Silacci C, Fernandez-Rodriguez BM, et al. (2010) Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 120: 1663-1673.
31. Nabel GJ, Fauci AS, (2010) Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat Med 16: 1389-1391.
32. Park KS, Seo YB, Lee JY, Im SJ, Seo SH, et al. (2011) Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e. Vaccine 29: 5481-5487.
33. Zhong W, He J, Tang X, Liu F, Lu X, et al. (2011) Development and evaluation of an M2-293FT cell-based flow cytometric assay for quantification of antibody response to native form of matrix protein 2 of influenza A viruses. J Immunol Methods 369: 115-124.
34. Liu W, Zou P, Ding J, Lu Y, Chen YH, (2005) Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design. Microbes Infect 7: 171-177.
35. Kawaoka Y, (1991) Equine H7N7 influenza A viruses are highly pathogenic in mice without adaptation: potential use as an animal model. J Virol 65: 3891-3894.